Greenphire, ERT Tie Patient Reporting and Compensation
Greenphire announced a strategic partnership with ERT
Greenphire, a provider of payment technology for the clinical trial industry, announced a strategic partnership with ERT, a provider of high-quality patient safety and efficacy endpoint data collection. The partnership will integrate Greenphire's ClinCard System with ERT's electronic patient reported outcomes (ePRO) technology. The goal is to link patient reporting to compensation to enhance patient engagement and compliance.
This partnership will enable sponsors and CROs to offer real-time compensation to patients for compliance with study protocols by linking their ePRO activity to a ClinCard personal debit card. In addition to using Greenphire's system to compensate participants with stipends for site visits, clients can customize out-of-office reimbursement for patients' time and effort based on the specific requirements of each protocol.
Read the full release here.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.
